Form: 3

Initial statement of beneficial ownership of securities

January 3, 2025

Documents

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Mukadam Sophie
(Last) (First) (Middle)
C/O BENITEC BIOPHARMA INC.
3940 TRUST WAY
(Street)
HAYWARD CA 94545
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2025 		3. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share 6,016 I By spouse
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options (right to buy) (1) 12/08/2030 Common Stock 141 50.66 D
Options (right to buy) (2) 06/13/2031 Common Stock 1,034 79.9 D
Options (right to buy) (3) 06/12/2033 Common Stock 5,294 3.91 D
Options (right to buy) (4) 03/05/2034 Common Stock 100,000 5.21 D
Options (right to buy) (5) 12/27/2034 Common Stock 300,000 12 D
Explanation of Responses:
1. The stock options vested in three substantially equal installments on December 9, 2021, December 9, 2022 and December 9, 2023.
2. The stock options vested in three substantially equal installments on June 14, 2022, June 14, 2023, and June 14, 2024.
3. Stock options for 1,764 shares vested on June 13, 2024. The remainder of the stock options will vest in two substantially equal installments on June 13, 2025 and June 13, 2026.
4. The stock options will vest in three substantially equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
5. The stock options will vest in sixteen substantially equal quarterly installments commencing on March 31, 2025.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Louis Rambo, Attorney-in-Fact for Sophie Mukadam 01/03/2025
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.